���景与受体作用机制 — Hands-On Walkthrough

By Editorial Desk · published 2025-07-30 · last reviewed 2025-09-09 · Data

ghrelin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.

背景与受体作用机制

现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。

Ipamorelin Background and Mechanism

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Ipamorelin at a glance

Ipamorelin Background and Receptor Pharmacology

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Related pages on this site

• Connected reference
• Automated report
• Verified comparison
• Efficient analysis
• Gradual primer
• Smart reference
• Optimized trends
• Lightweight primer

Analytical Characterisation and Storage

The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.

Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.

Handling, Storage and Analytical Verification

Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.

Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.

Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.

Receptor Selectivity and Secretagogue Signaling

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Further detail

Casuarinas are flowering plants with fruit and leaves resembling the leaves and cones of the gymnosperm pines Some dicots (Anemone) and monocots (Trillium) in inhospitable environments are able to form underground organs such as corms, bulbs and rhizomes for reserving of nutrition and water until the conditions become better. Carnivorous plants: nitrogen-deficient plants have in at least seven distinct times become carnivorous, like: flypaper traps such as sundews and butterworts, spring traps-Venus fly trap, and pitcher traps in order to capture and digest insects to obtain scarce nitrogen. Pitcher plants: the pitcher trap evolved independently in three eudicot lineages and one monocot lineage. Similar-looking rosette succulents have arisen separately among plants in the families Asphodelaceae (formerly Liliaceae) and Crassulaceae. The orchids, the birthwort family and Stylidiaceae have evolved independently the specific organ known as gynostemium, more popular as column. The Euphorbia of deserts in Africa and southern Asia, and the Cactaceae of the New World deserts have similar modifications (see picture below for one of many possible examples). Sunflower: some types of sunflower and Pericallis are due to convergent evolution. Crassulacean acid metabolism (CAM), a carbon fixation pathway that evolved in multiple plants as an adaptation to arid conditions. C4 photosynthesis is estimated to have evolved over 60 times within plants, via multiple different sequences of evolutionary events.

Most cases of SCID are due to mutations in the IL2RG gene encoding the common gamma chain (γc) (CD132), a protein that is shared by the receptors for interleukins IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. These interleukins and their receptors are involved in the development and differentiation of T and B cells. Because the common gamma chain is shared by many interleukin receptors, mutations that result in a non-functional common gamma chain cause widespread defects in interleukin signalling. The result is a near complete failure of the immune system to develop and function, with low or absent T cells and NK cells and non-functional B cells.The common gamma chain is encoded by the gene IL-2 receptor gamma, or IL-2Rγ, which is located on the X-chromosome. For this reason, immunodeficiency caused by mutations in IL-2Rγ is known as X-linked severe combined immunodeficiency. The condition is inherited in an X-linked recessive pattern.

Glutathione peroxidase 3 (GPx-3), also known as plasma glutathione peroxidase (GPx-P) or extracellular glutathione peroxidase is an enzyme that in humans is encoded by the GPX3 gene. GPx-3 belongs to the glutathione peroxidase family, which functions in the detoxification of hydrogen peroxide. It contains a selenocysteine (Sec) residue at its active site. The selenocysteine is encoded by the UGA codon, which normally signals translation termination. The 3' UTR of Sec-containing genes have a common stem-loop structure, the sec insertion sequence (SECIS), which is necessary for the recognition of UGA as a Sec codon rather than as a stop signal.

Receptor binding – Most drugs exert their effects by binding to specific cell receptors (proteins on cell surfaces or inside cells) Dose-response relationship – Illustrated using drug-response curves, these relationships show the effect of different drug doses on the magnitude of a response. Therapeutic window – The range of doses between the minimum effective concentration and the minimum toxic concentration.

Sources: en.wikipedia.org

Supporting material

== Side effects == Side effects of dextromethorphan/bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction (including abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia), hyperhidrosis, anxiety, constipation, decreased appetite, insomnia, arthralgia, fatigue, paresthesia, and blurred vision. These side effects occurred at rates ≥2% and to a greater extent than with placebo in clinical trials.

1 December Astronomers using the James Webb Space Telescope report viewing clouds, likely made of methane, moving across Saturn's moon Titan. Genomic epidemiologists report results from a global survey of antimicrobial resistance (AMR) via genomic wastewater-based epidemiology, finding large regional variations, providing maps, and suggesting resistance genes are also passed on between microbial species that are not closely related. On 9 December, the WHO's fifth GLASS report summarizes 2020 data on inter-national AMR, including various new features and an interactive dashboard. Scientists report the measurement of the highest toughness ever recorded, of any material, while investigating a metallic alloy made of chromium, cobalt, and nickel. 4 December – Chemical engineers report a method to substantially increase conversion efficiency and reduce material costs of green hydrogen production by using sound waves during electrolysis. 5 December Construction begins on the Square Kilometer Array, the largest telescope in history. A review summarizes current scientific data about cardiovascular health effects of a large number of dietary supplements and micronutrients, including with a heat map visualizing evidence quality and health impact direction of each. Health/eco-economics: A study projects the costs of inaction on physical inactivity in terms of number of cases of preventable major NCDs and healthcare system finances. Results of a trial investigating financial incentives for health, in particular for weight loss, are reported (5 Dec).

In March 1916 (BR.23–BR.26), Robertson announced the results of a series of experiments that he and his assistant, Louis Adolph Ray, had conducted with the white mice — chosen as his "experimental animal" because of their "hardiness, rapid growth, smallness, and fecundity" (BR.23, p.366) — wherein the oral administration of tethelin, a "growth-controlling principle" (which they later described as "the ether-precipitable fraction of an alcoholic extract of the anterior lobe of the pituitary body"), produced precisely "the same effects on their growth" as those "which [had] accompan[ied] the [oral] administration of the whole tissue of the anterior lobe of the pituitary body" to his control group (BR.25, p.397). As Everitt (AE.2, p.63) notes — having distinguished (p.66) Robertson and Ray's "growth controlling principle" of the pituitary (BR.35) from Moon, et al.'s "growth stimulating principle" (HM.2) — it was not until the (1921) work of Herbert Evans and Joseph Long (HE.1; HE.2) that "[it was] conclusively proved that the pituitary contained a growth-stimulating hormone". Evans and Long also discovered that, whilst the oral administration of their "pituitary principle" had no effect, administration per medium of an intraperitoneal injection was effective: which led them to the conclusion that whatever the pituitary's 'active principle' might be, it was "digested in the alimentary canal".

== P == Paracelsus (1493–1541), alchemist Rudolph Pariser (1923–2021), theoretical and organic chemist Robert G. Parr (1921–2017), theoretical chemist Louis Pasteur (1822–1895), French biochemist, father of pasteurization Linus Pauling (1901–1994), Nobel Prizes in chemistry and peace Charles J. Pedersen (1904–1989), 1987 Nobel Prize in Chemistry Eugène-Melchior Péligot (1811–1890), French chemist who isolated the uranium metal William Henry Perkin (1838–1907), British organic chemist and inventor of mauveine (dye) William Henry Perkin, Jr. (1860–1929), British organic chemist, son of Sir William Henry Perkin Max Perutz (1914–2002), 1962 Nobel Prize in Chemistry Eva Philbin (1914–2005), Irish chemist David Andrew Phoenix (born 1966), British biochemist Georgy Pigulevsky (1888–1964), Russian chemist and biochemist James Pitts (1921–2014), American chemist known for work on photochemistry and atmospheric chemistry Roy J. Plunkett (1910–1994), discoverer of Teflon John Charles Polanyi (born 1929), Canadian chemist, Nobel Prize in Chemistry 1986 John A.

=== Soft nanoparticles === Most soft nanoparticles have core–shell structures. The semiflexible surface ligands soften the interaction of the cores and create a more spherical shape than the underlying core from uniform coverage. The surface ligands can be chosen from surfactants, polymers, DNA, ions, etc. Tuning the structure of superlattices can be achieved by varying the amount of surface ligands. Their "soft" behavior results in different self-assembly rules from hard particles, where Pauling's rules expired. To tailor the superlattice structure of soft nanoparticles, six design rules of spherical nanoparticle superlattice are established based on the study of metal–DNA nanoparticles:

Sources: en.wikipedia.org

Frequently asked questions